文献速递心境障碍会诊联络精神医学

司美格鲁肽对重性抑郁障碍努力型决策的影响:随机临床试验

Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

这项16周双盲安慰剂对照平行组随机临床试验纳入72例BMI≥25的重性抑郁障碍患者,随机接受口服司美格鲁肽14mg或安慰剂辅助常规治疗。司美格鲁肽组在奖励期望值更高时表现出更强的付出体力努力意愿(治疗×访视×期望值交互χ2=12.024,P=.02),计算建模显示其效应源于努力折扣减少,努力敏感性显著降低(β=-1.737,P=.03),而概率敏感性无治疗效应(β=-0.776,P=.51)。

要点

  • 司美格鲁肽可改善重性抑郁障碍患者的动机相关决策表现
  • 效应机制为降低努力感知成本而非改变概率敏感性
  • 结果为伴有奖励功能障碍的神经精神障碍治疗提供线索

核心结论

  • 在重性抑郁障碍患者中,口服司美格鲁肽14mg辅助常规治疗16周可显著改善动机测量指标。
  • 司美格鲁肽相对于金钱奖励降低了感知的努力成本,表现为努力折扣减少。

研究设计与样本

  • 16周双盲安慰剂对照平行组随机临床试验,纳入72例重性抑郁障碍且BMI≥25的参与者,随机接受口服司美格鲁肽(n=35)或安慰剂(n=37)。
  • 口服司美格鲁肽14mg从4mg起始、采用4周剂量递增方案,辅助常规治疗;参与者来自多伦多大学健康网络心境障碍精神药理学单元。

主要发现

  • 司美格鲁肽组在奖励期望值更高时表现出更强的付出体力努力意愿(治疗×访视×期望值交互χ2=12.024;P=.02)。
  • 计算建模显示司美格鲁肽对选择行为的影响源于努力折扣减少。
  • 司美格鲁肽治疗显著降低努力敏感性(β=-1.737;P=.03)。
  • 司美格鲁肽对概率敏感性无治疗效应(β=-0.776;P=.51)。

关键数值与推荐

  • 预设的次要分析结局为努力-支出奖励任务(EEfRT)表现。
  • 试验注册号:ClinicalTrials.gov NCT04466345。

临床怎么用

  • 司美格鲁肽可能作为辅助治疗改善重性抑郁障碍患者的动机缺陷,尤其针对努力相关奖励功能障碍。
  • 临床决策需结合患者BMI≥25及常规治疗背景,并关注其对努力折扣的潜在影响。

局限性

  • 本研究为二次分析,样本量72例,结果需在更大样本中验证。
  • 研究人群限于BMI≥25的重性抑郁障碍患者,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Consistent results from preclinical and clinical studies indicate that activation of glucagon-like peptide-1 receptors (GLP-1 Rs) affects reward processes; however, to our knowledge, no study has previously evaluated whether a GLP-1 R agonist (GLP-1 RA) affects motivated behavior in individuals with major depressive disorder (MDD) in a randomized clinical trial. OBJECTIVE: To assess the effects of a GLP-1 RA, semaglutide, on reward-related dysfunction in a population with MDD. DESIGN, SETTING, AND PARTICIPANTS: This study was a 16-week, double-blind, placebo-controlled, parallel-group randomized clinical trial. A total of 72 participants with a diagnosis of MDD and a body mass index (calculated as weight in kilograms divided by height in meters squared) of 25 or higher were randomized to oral semaglutide (n = 35) or placebo (n = 37). Participants were recruited from the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, a university-based mood disorders program. Participants were enrolled between March 14, 2022, and July 26, 2024. Data analysis was performed from January 7, 2025, through February 3, 2025. INTERVENTION: Patients were randomized 1:1 to receive placebo or oral semaglutide, 14 mg (initiated at 4 mg and titrated using a 4-week dose-escalation regimen), adjunctive to their treatment as usual. MAIN OUTCOME AND MEASURE: The preregistered outcome of this secondary analysis was performance on the Effort-Expenditure for Rewards Task (EEfRT). RESULTS: A total of 72 participants were randomized to oral semaglutide (n = 35 [49.7%]; mean [SD] age, 38.17 [11.79] years; 18 female participants [51.4%]) or placebo (n = 37 [51.3%]; mean [SD] age, 40.27 [9.32] years; 19 female participants [51.3%]). Semaglutide-treated participants exhibited a pattern of increased willingness to exert physical efforts with higher expected values of reward (treatment × visit × expected value interaction: χ2 = 12.024; P = .02). Computational modeling indicated that semaglutide's effects on choice behavior were a result of reduced effort discounting. Sensitivity to effort was significantly reduced by treatment with semaglutide (β = -1.737; P = .03), whereas there was no treatment effect on sensitivity to probability (β = -0.776; P = .51). CONCLUSIONS AND RELEVANCE: In this secondary analysis of a double-blind randomized clinical trial, treatment with semaglutide significantly improved measures of motivation in patients with MDD. Semaglutide reduced the perceived cost of effort, relative to the monetary reward; the results of this trial have implications for the treatment of multiple neuropsychiatric disorders, which are characterized by varied reward dysfunctions. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04466345.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Gill H, Badulescu S, Shah H, et al. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 42054055. doi:10.1001/jamapsychiatry.2026.0594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。